Insider Selling: Olema Pharmaceuticals (NASDAQ:OLMA) Director Sells $144,750.00 in Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 12,500 shares of the stock in a transaction that occurred on Thursday, July 23rd. The stock was sold at an average price of $11.58, for a total value of $144,750.00. Following the sale, the director directly owned 715,270 shares in the company, valued at $8,282,826.60. This represents a 1.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Olema Pharmaceuticals Price Performance

Shares of NASDAQ OLMA opened at $11.82 on Friday. The stock has a market capitalization of $1.03 billion, a PE ratio of -5.85 and a beta of 2.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.88 and a quick ratio of 10.88. The business has a fifty day moving average price of $11.46 and a two-hundred day moving average price of $16.57. Olema Pharmaceuticals, Inc. has a fifty-two week low of $4.47 and a fifty-two week high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.52). As a group, equities analysts predict that Olema Pharmaceuticals, Inc. will post -2.22 earnings per share for the current fiscal year.

Institutional Trading of Olema Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Siren L.L.C. bought a new position in Olema Pharmaceuticals in the fourth quarter valued at about $82,518,000. Janus Henderson Group PLC lifted its holdings in shares of Olema Pharmaceuticals by 87.1% in the fourth quarter. Janus Henderson Group PLC now owns 6,710,194 shares of the company’s stock worth $167,901,000 after acquiring an additional 3,124,345 shares during the last quarter. Cormorant Asset Management LP bought a new position in shares of Olema Pharmaceuticals in the fourth quarter worth about $68,750,000. RA Capital Management L.P. acquired a new stake in shares of Olema Pharmaceuticals in the 4th quarter valued at approximately $65,000,000. Finally, Bain Capital Life Sciences Investors LLC boosted its stake in shares of Olema Pharmaceuticals by 24.3% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock valued at $212,716,000 after purchasing an additional 1,664,687 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on OLMA. Wall Street Zen downgraded shares of Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Friday, July 17th. Guggenheim cut their price target on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Finally, HC Wainwright reiterated a “buy” rating on shares of Olema Pharmaceuticals in a research report on Friday, May 22nd. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Olema Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $44.10.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.